Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Revenue (2020 - 2024)

Goldenwell Biotech's Revenue history spans 5 years, with the latest figure at -$158.0 for Q4 2024.

  • For Q4 2024, Revenue fell 160.77% year-over-year to -$158.0; the TTM value through Sep 2025 reached -$158.0, down 139.6%, while the annual FY2024 figure was $139.0, 92.43% down from the prior year.
  • Revenue reached -$158.0 in Q4 2024 per GWLL's latest filing, down from $139.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $43690.0 in Q3 2022 to a low of -$158.0 in Q4 2024.
  • Average Revenue over 5 years is $5254.2, with a median of $397.0 recorded in 2022.
  • Peak YoY movement for Revenue: soared 22020.0% in 2021, then plummeted 160.77% in 2024.
  • A 5-year view of Revenue shows it stood at $5.0 in 2020, then skyrocketed by 98040.0% to $4907.0 in 2021, then skyrocketed by 790.36% to $43690.0 in 2022, then crashed by 99.4% to $260.0 in 2023, then tumbled by 160.77% to -$158.0 in 2024.
  • Per Business Quant, the three most recent readings for GWLL's Revenue are -$158.0 (Q4 2024), $139.0 (Q2 2024), and $260.0 (Q4 2023).